Jean Holloway Sells 977 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) SVP Jean Holloway sold 977 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $28.49, for a total value of $27,834.73. Following the completion of the transaction, the senior vice president directly owned 184,118 shares in the company, valued at approximately $5,245,521.82. The trade was a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Artivion Stock Performance

AORT traded up $0.38 on Wednesday, reaching $28.77. 758,936 shares of the stock were exchanged, compared to its average volume of 593,839. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.47 and a quick ratio of 2.51. The company’s 50-day moving average price is $23.79 and its 200 day moving average price is $30.81. The firm has a market capitalization of $1.40 billion, a PE ratio of -410.94 and a beta of 1.25. Artivion, Inc. has a fifty-two week low of $19.16 and a fifty-two week high of $48.25.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter. The firm had revenue of $125.76 million during the quarter, compared to analysts’ expectations of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. As a group, sell-side analysts forecast that Artivion, Inc. will post 0.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of AORT. Royal Bank of Canada increased its stake in shares of Artivion by 107.0% in the 1st quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock valued at $952,000 after purchasing an additional 20,010 shares in the last quarter. AQR Capital Management LLC grew its holdings in Artivion by 8.8% in the first quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock valued at $862,000 after purchasing an additional 2,823 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Artivion by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock valued at $580,000 after buying an additional 1,032 shares in the last quarter. Creative Planning raised its stake in shares of Artivion by 5.6% during the 2nd quarter. Creative Planning now owns 14,272 shares of the company’s stock worth $444,000 after buying an additional 753 shares during the period. Finally, Invesco Ltd. raised its stake in shares of Artivion by 40.8% during the 2nd quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock worth $14,960,000 after buying an additional 139,370 shares during the period. Institutional investors and hedge funds own 86.37% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Citizens Jmp cut their price objective on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a research note on Friday, May 8th. Stifel Nicolaus set a $45.00 target price on shares of Artivion in a research report on Monday, June 1st. Wall Street Zen lowered shares of Artivion from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Weiss Ratings lowered Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday. Finally, Needham & Company LLC reissued a “buy” rating and issued a $44.00 price objective on shares of Artivion in a report on Monday, July 20th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Artivion has a consensus rating of “Moderate Buy” and an average price target of $44.67.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.